Show simple item record

dc.contributor.authorSumer, Sua
dc.contributor.authorAktug Demir, Nazlim
dc.contributor.authorKölgelier, Servet
dc.contributor.authorCagkan Inkaya, Ahmet
dc.contributor.authorArpaci, Abdullah
dc.contributor.authorSaltuk Demir, Lütfi
dc.contributor.authorUral, Onur
dc.date.accessioned2019-12-10T11:20:43Z
dc.date.available2019-12-10T11:20:43Z
dc.date.issued2013
dc.identifier.issn1735-143X
dc.identifier.urihttps://doi.org/10.5812/hepatmon.10106
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3768234/
dc.identifier.urihttp://hdl.handle.net/11655/15375
dc.description.abstractBackground Serum apoptotic cytokeratine 18 neoepitope M30 (CK-18 M30) and matrix metalloproteinase 2 (MMP-2) have been popular markers for detecting liver fibrosis in recent years. CK-18 is a major intermediate filament protein in liver cells and one of the most prominent substrates of caspases during hepatocyte apoptosis. MMP-2 plays an important role in tissue remodeling and repairing processes during physiological and pathological states. Objectives The objective of this study was to investigate the significance of CK-18 M30 and MMP-2 levels for clinical use in patients with chronic hepatitis B (CHB), as well as their sensitivity in determining cirrhotic patients. Patients and Methods This study included 189 CHB patients and 51 healthy controls. A modified Knodell scoring system was used to determine the fibrosis level in chronic hepatitis B patients. CK-18 M30 levels were determined with an M30-Apoptosense ELISA assay. MMP-2 levels were determined with the ELISA assay. Results The study group consisted of 132 (69.8%) males and 57 (30.2%) females, and the control group consisted of 25 males (49.0%) and 26 females (51%). Patients’ CK-18 M30 levels were higher than values of the control group (308 [1–762] vs. 168 [67–287], P=0.001). Serum MMP-2 levels were found to be statistically higher in the patient group with respect to the controls (3.0 [1.1–6.8] vs. 2.0 [1.2–3.4], P=0.001). The highest serum CK-18 M30 and MMP-2 levels were measured in patients with cirrhosis. Serum apoptotic CK-18 M30 levels positively correlated with advanced age, fibrosis stage, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels (P= 0.001, 0.033, 0.001, and 0.001, respectively). Serum MMP-2 levels positively correlated with fibrosis stage, serum ALT, and AST levels (P= 0.001, 0.001, and 0.001, respectively). Conclusions Our study indicated that CK-18 M30 and MMP-2 levels were higher in CHB patients compared to healthy controls and they were in association with significant hepatic fibrosis, especially cirrhosis.
dc.relation.isversionof10.5812/hepatmon.10106
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleThe Clinical Significance of Serum Apoptotic Cytokeratin 18 Neoepitope M30 (Ck-18 M30) and Matrix Metalloproteinase 2 (Mmp-2) Levels in Chronic Hepatitis B Patients with Cirrhosis
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalHepatitis Monthly
dc.contributor.departmentİç Hastalıkları
dc.identifier.volume13
dc.identifier.issue6
dc.description.indexPubMed
dc.description.indexWoS


Files in this item

This item appears in the following Collection(s)

Show simple item record